Dynavax Technologies | DVAX - Sales Revenues


Dynavax Technologies reported $95.44M in Sales Revenues for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Adma Biologics USD 121.98M 4.43M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Dynavax Technologies USD 95.44M 30.44M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
Glaxosmithkline GBP 7.99B 131M Jun/2025
Merck USD 15.81B 280M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
TG Therapeutics USD 141.1M 21.4M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025